US2006229274A1PendingUtilityA1

Weight reduction and inhibition of hypertriglyceridemia medicine containing ATP as effective ingredient

34
Individually held — no corporate assignee on recordPriority: May 8, 2002Filed: Jun 15, 2006Published: Oct 12, 2006
Est. expiryMay 8, 2022(expired)· nominal 20-yr term from priority
Inventors:Chao Hsue
A61K 31/7076
34
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A weight reduction and inhibition of Hypertriglyceridemia medicine contain ATP as an effective ingredient, and more particularly to one that takes advantage of a cyclic adenosine monophosphate (Cyclic AMP) produced from the decomposed ATP in human body to promote the increase of lipase, thus to activate the metabolism and decomposition of triglyceride in the human body.

Claims

exact text as granted — not AI-modified
1 . A weight reduction and inhibition of hypertriglyceridemia composition comprising an effective amount of adenosine triphosphate (ATP) in a form that is suitable to be used externally and to be absorbed from skin.  
   
   
       2 . The weight reduction and inhibition of hypertriglyceridemia composition comprising an effective amount of adenosine triphosphate (ATP) as defined  claim 1 , wherein said the effective amount of adenosine triphosphate (ATP) in a form that is suitable to be used nasally and to be absorbed from nasal mucous membrane.  
   
   
       3 . The weight reduction and inhibition of hypertriglyceridemia composition comprising an effective amount of adenosine triphosphate (ATP) as defined  claim 1 , wherein said the effective amount of adenosine triphosphate (ATP) in a form that is suitable to be injected and to be absorbed intramuscularly.  
   
   
       4 . The weight reduction and inhibition of hypertriglyceridemia composition comprising an effective amount of adenosine triphosphate (ATP) as defined  claim 1 , wherein said the effective amount of adenosine triphosphate (ATP) in a form that is suitable to be injected and to be absorbed intravenously.  
   
   
       5 . The weight reduction and inhibition of hypertriglyceridemia composition comprising an effective amount of adenosine triphosphate (ATP) as defined  claim 1 , wherein said the effective amount of adenosine triphosphate (ATP) in a form that is suitable to be used rectally and to be absorbed from lower segment of intestinal tract.  
   
   
       6 . A weight reduction and inhibition of hypertriglyceridemia composition comprising an effective amount of adenosine triphosphate (ATP) and an effective amount of at least one inhibitor selected from the group consisting of 1,3,7-trimethy-xantine, 1,3-dimethyl-xanthine and a 3,7-dimethyl-xanthine, wherein said the weight reduction and inhibition of hypertriglyceridemia composition comprising an effective amount of adenosine triphosphate (ATP) and an effective amount of at least one inhibitor selected from the group consisting of 1,3,7-trimethy-xantine, 1,3-dimethyl-xanthine and a 3,7-dimethyl-xanthine in a form that is suitable to be injected and to be absorbed intramuscularly.  
   
   
       7 . The weight reduction and inhibition of hypertriglyceridemia composition comprising an effective amount of adenosine triphosphate (ATP) and an effective amount of at least one inhibitor selected from the group consisting of 1,3,7-trimethy-xantine, 1,3-dimethyl-xanthine and a 3,7-dimethyl-xanthine as defined claims  1  or  6 , wherein said the adenosine triphosphate (ATP) and an effective amount of at least one inhibitor selected from the group consisting of 1,3,7-trimethy-xantine, 1,3-dimethyl-xanthine and a 3,7-dimethyl-xanthine in a form that is suitable to be used nasally and to be absorbed from nasal mucous membrane.  
   
   
       8 . The weight reduction and inhibition of hypertriglyceridemia composition comprising an effective amount of adenosine triphosphate (ATP) and an effective amount of at least one inhibitor selected from the group consisting of 1,3,7-trimethy-xantine, 1,3-dimethyl-xanthine and a 3,7-dimethyl-xanthine as defined claims  1  or  6 , wherein said the adenosine triphosphate (ATP) and an effective amount of at least one inhibitor selected from the group consisting of 1,3,7-trimethy-xantine, 1,3-dimethyl-xanthine and a 3,7-dimethyl-xanthine in a form that is suitable to be injected and to be absorbed intravenously.  
   
   
       9 . The weight reduction and inhibition of hypertriglyceridemia composition comprising an effective amount of adenosine triphosphate (ATP) and an effective amount of at least one inhibitor selected from the group consisting of 1,3,7-trimethy-xantine, 1,3-dimethyl-xanthine as defined claims  1  or  6 , wherein said the adenosine triphosphate (ATP) and an effective amount of at least one inhibitor selected from the group consisting of 1,3,7-trimethy-xantine, 1,3-dimethyl-xanthine and a 3,7-dimethyl-xanthine in a form that is suitable to be used externally and to be absorbed from skin.  
   
   
       10 . The weight reduction and inhibition of hypertriglyceridemia composition comprising an effective amount of adenosine triphosphate (ATP) and an effective amount of at least one inhibitor selected from the group consisting of 1,3,7-trimethy-xantine, 1,3-dimethyl-xanthine and a 3,7-dimethyl-xanthine as defined claims  1  or  6 , wherein said the adenosine triphosphate (ATP) and an effective amount of at least one inhibitor selected from the group consisting of 1,3,7-trimethy-xantine, 1,3-dimethyl-xanthine and a 3,7-dimethyl-xanthine in a form that is suitable to be used rectally and to be absorbed from lower segment of intestinal tract.  
   
   
       11 . A weight reduction and inhibition of hypertriglyceridemia composition comprising an effective amount of non-salt form dephosphorylatable adenosine triphosphate (ATP), wherein said the weight reduction and inhibition of hypertriglyceridemia composition promotes activation and increase lipase to facilitate decomposition and metabolism of triglyceride for removing fat accumulated in a human body.  
   
   
       12 . The weight reduction and inhibition of hypertriglyceridemia composition comprising an effective amount of non-salt form dephosphorylatable adenosine triphosphate (ATP) as defined  claim 11 , wherein said the weight reduction and inhibition of hypertriglyceridemia composition comprising an effective amount of non-salt form dephosphorylatable adenosine triphosphate (ATP) and an effective amount of at least one inhibitor selected from the group consisting of 1,3,7-trimethy-xantine, 1,3-dimethyl-xanthine and a 3,7-dimethyl-xanthine, so as to the weight reduction and inhibition of hypertriglyceridemia composition promotes activation and increase lipase to facilitate decomposition and metabolism of triglyceride for removing fat accumulated in a human body.  
   
   
       13 . A weight reduction and inhibition of hypertriglyceridemia composition comprising an effective amount of cyclic AMP (cAMP) or physiologically acceptable salt thereof or both in a form that is suitable to be taken orally and to be absorbed from gastrointestinal tract.  
   
   
       14 . The weight reduction and inhibition of hypertriglyceridemia composition comprising an effective amount of cyclic AMP (cAMP) or physiologically acceptable salt thereof or both and an effective amount of at least one inhibitor selected from the group consisting of 1,3,7-trimethy-xantine, 1,3-dimethyl-xanthine and a 3,7-dimethyl-xanthine as defined  claim 13 , wherein said the weight reduction and inhibition of hypertriglyceridemia composition comprising an effective amount of cyclic AMP (cAMP) or physiologically acceptable salt thereof or both and an effective amount of at least one inhibitor selected from the group consisting of 1,3,7-trimethy-xantine, 1,3-dimethyl-xanthine and a 3,7-dimethyl-xanthine in a form that is suitable to be taken orally and to be absorbed from gastrointestinal tract.  
   
   
       15 . A weight reduction and inhibition of hypertriglyceridemia composition comprising an effective amount of cyclic AMP (cAMP) or physiologically acceptable salt thereof or both in a form that is suitable to be absorbed from skin.  
   
   
       16 . The weight reduction and inhibition of hypertriglyceridemia composition comprising an effective amount of cyclic AMP (cAMP) or physiologically acceptable salt thereof or both and an effective amount of at least one inhibitor selected from the group consisting of 1,3,7-trimethy-xantine, 1,3-dimethyl-xanthine and a 3,7-dimethyl-xanthine as defined  claim 15 , wherein said the weight reduction and inhibition of hypertriglyceridemia composition comprising an effective amount of cyclic AMP (cAMP) or physiologically acceptable salt thereof or both and an effective amount of at least one inhibitor selected from the group consisting of 1,3,7-trimethy-xantine, 1,3-dimethyl-xanthine and a 3,7-dimethyl-xanthine in a form that is suitable to be used externally and to be absorbed from skin.  
   
   
       17 . A weight reduction and inhibition of hypertriglyceridemia composition comprising an effective amount of cyclic AMP (cAMP) or physiologically acceptable salt thereof or both in a form that is suitable to be used nasally and to be absorbed from nasal mucous membrane.  
   
   
       18 . The weight reduction and inhibition of hypertriglyceridemia composition comprising an effective amount of cyclic AMP (cAMP) or physiologically acceptable salt thereof or both and an effective amount of at least one inhibitor selected from the group consisting of 1,3,7-trimethy-xantine, 1,3-dimethyl-xanthine and a 3,7-dimethyl-xanthine as defined  claim 17 , wherein said the weight reduction and inhibition of hypertriglyceridemia composition comprising an effective amount of cyclic AMP (cAMP) or physiologically acceptable salt thereof or both and an effective amount of at least one inhibitor selected from the group consisting of 1,3,7-trimethy-xantine, 1,3-dimethyl-xanthine and a 3,7-dimethyl-xanthinein a form that is suitable to be used nasally and to be absorbed from nasal mucous membrane.  
   
   
       19 . A weight reduction and inhibition of hypertriglyceridemia composition comprising an effective amount of cyclic AMP (cAMP) or physiologically acceptable salt thereof or both in a form that is suitable to be injected and to be absorbed intramuscularly.  
   
   
       20 . The weight reduction and inhibition of hypertriglyceridemia composition comprising an effective amount of cyclic AMP (cAMP) or physiologically acceptable salt thereof or both and an effective amount of at least one inhibitor selected from the group consisting of 1,3,7-trimethy-xantine, 1,3-dimethyl-xanthine and a 3,7-dimethyl-xanthine as defined  claim 19 , wherein said the weight reduction and inhibition of hypertriglyceridemia composition comprising an effective amount of cyclic AMP (cAMP) or physiologically acceptable salt thereof or both and an effective amount of at least one inhibitor selected from the group consisting of 1,3,7-trimethy-xantine, 1,3-dimethyl-xanthine and a 3,7-dimethyl-xanthine in a form that is suitable to be injected and to be absorbed intramuscularly.  
   
   
       21 . A weight reduction and inhibition of hypertriglyceridemia composition comprising an effective amount of cyclic AMP (cAMP) or physiologically acceptable salt thereof or both in a form that is suitable to be injected and to be absorbed intravenously.  
   
   
       22 . The weight reduction and inhibition of hypertriglyceridemia composition comprising an effective amount of cyclic AMP (cAMP) or physiologically acceptable salt thereof or both and an effective amount of at least one inhibitor selected from the group consisting of 1,3,7-trimethy-xantine, 1,3-dimethyl-xanthine and a 3,7-dimethyl-xanthine as defined  claim 21 , wherein said the weight reduction and inhibition of hypertriglyceridemia composition comprising an effective amount of cyclic AMP (cAMP) or physiologically acceptable salt thereof or both and an effective amount of at least one inhibitor selected from the group consisting of 1,3,7-trimethy-xantine, 1,3-dimethyl-xanthine and a 3,7-dimethyl-xanthine in a form that is suitable to be injected and to be absorbed intravenously.  
   
   
       23 . A weight reduction and inhibition of hypertriglyceridemia composition comprising an effective amount of cyclic AMP (cAMP) or physiologically acceptable salt thereof or both in a form that is suitable to be used rectally and to be absorbed from lower segment of intestinal tract.  
   
   
       24 . The weight reduction and inhibition of hypertriglyceridemia composition comprising an effective amount of cyclic AMP (cAMP) or physiologically acceptable salt thereof or both and an effective amount of at least one inhibitor selected from the group consisting of 1,3,7-trimethy-xantine, 1,3-dimethyl-xanthine and a 3,7-dimethyl-xanthine as defined  claim 23 , wherein said the weight reduction and inhibition of hypertriglyceridemia composition comprising an effective amount of cyclic AMP (cAMP) or physiologically acceptable salt thereof or both and an effective amount of at least one inhibitor selected from the group consisting of 1,3,7-trimethy-xantine, 1,3-dimethyl-xanthine and a 3,7-dimethyl-xanthine in a form that is suitable to be used rectally and to be absorbed from lower segment of intestinal tract.

Join the waitlist — get patent alerts

Track US2006229274A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.